In this episode of "In the Interim...", Dr. Scott Berry investigates the practical meaning of fairness by connecting a controversial World Cup soccer ruling to foundational questions in clinical trial statistics.

On the latest episode of "In the Interim...", Dr. Scott Berry and Dr. Kert Viele deliver a focused, technical analysis of statistical bias when stopping trials early.

On the latest episode of "In the Interim…", Dr. Scott Berry provides an empirical examination of two recent JAMA trials: TRACK (low-dose rivaroxaban in advanced kidney disease) and VICTORY (IV vitamin C in severe burn injury).

In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele examine response-adaptive randomization (RAR) in clinical trials, dissecting its statistical rationale, common criticisms, and implementation challenges.

In this episode of "In the Interim…", Dr. Scott Berry explores the origins of REMAP-CAP with Prof. Steve Webb, former chair of the REMAP-CAP International Trial Steering Committee.

In this episode of "In the Interim…", Dr. Scott Berry explores the challenge of protracted endpoint timelines in adaptive clinical trials and the statistical strategies used to increase the rate of actionable information gain.